TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Combined operating time for hemicraniectomy and cranioplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of cerebrospinal fluid effusion
Endpoint domain: Adverse events/effects
Primary endpoint: Chlamydia screening rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in PNIF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in serum IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: prolonged postoperative respiration time/stay in the intensive care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital Capacity (VC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced Expiratory Volume in 1 second (FEV₁)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Propofol consumption during extended anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intention-to-treat all-species efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCR-adjusted falciparum efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasitemia at Day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythema extent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean bleeding/spotting days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean satisfaction with bleeding profiles
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fat mass (FM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fat-free mass (FFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fat mass percentage (FM%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Return to normal activities within 3 days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: death or any stroke at 30 days after procedure
Endpoint domain: Mortality/survival
Primary endpoint: risk of death, any stroke, or myocardial infarction at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: ipsilateral ischaemic stroke at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: local recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fat-free mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of subjects who remained continuously abstinent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cardiac event rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: acute asthma medical visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anal resting pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anal pressure during evacuation reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of excess weight loss at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting ghrelin levels at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Metabolic parameters (leptin, glucose, insulin, C-peptide, glycated hemoglobin, insulin resistance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cumulative work
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target blood pressure achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate for ALT treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final IOP > or = 21 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cessation at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confidence in quitting
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CRC screening rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-efficacy for coping with cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: patient competencies such as self-regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: managing emotional distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total calculated output contrast mass error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Goodness of fit (R2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injected Mass Error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardioversion success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Growth as indicated by weight, length, and head circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of OT intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour chest tube output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: blood product unit exposures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total consumption of analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Demand for analgesic medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of varices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Variceal progression or bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall stroke risk
Endpoint domain: Mortality/survival
Primary endpoint: Ischemic stroke risk
Endpoint domain: Mortality/survival
Primary endpoint: C-reactive protein reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of calcium oxalate stone disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: analgesic medication necessary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: procedure duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain reported
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Orthostatic pulse change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relative volume deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive orthostatic tilt test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean gestational age at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Very preterm birth (PTB) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Mean birthweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hematoma expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unfavorable outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cophysical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's percent energy from core foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in overall scalp condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in epidermal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in biomarkers of epidermal barrier integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in SCORAD index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Total anesthesia time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of bradycardia
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: IOP elevations > or = 10 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Percocet ingestion at 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of communication skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed tumor responses (PR + CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Median times to progression (TTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to achieve biochemical euthyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: time to sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vital signs changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity for intermediate vision conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Refractive predictability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombolysis success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of obstructive thrombi or stroke
Endpoint domain: Adverse events/effects
Primary endpoint: Cisplatin distribution in the mesenteric peritoneum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative severe complications rate
Endpoint domain: Adverse events/effects
Primary endpoint: Complete ablation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local tumour progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Skin color and thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Hearing threshold levels at frequencies 2-8 kHz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak torque during knee extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: walking ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: neutrophil chemotaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: natural killer cell cytotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum concentration of IgG against antigen 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum chromium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: cephalic vein diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Tolerability of etanercept
Endpoint domain: Adverse events/effects
Primary endpoint: fat avoidance behaviours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time oriented towards familiar scent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of nasal obstruction severity and frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of nasal volume and total nasal resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of olfaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five-year disease-free survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort of use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete lesion response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subject-reported pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: subject satisfaction regarding convenience and outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of death at 28 days
Endpoint domain: Mortality/survival
Primary endpoint: Arrhythmic events
Endpoint domain: Adverse events/effects
Primary endpoint: Heat pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laser pinprick threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Habituation of sympathetic sudomotor responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance to rofecoxib
Endpoint domain: Adverse events/effects
Primary endpoint: Reception time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of undetectable HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysplastic lesions miss rate per subject
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of dysplastic lesions identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in hepatic function indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of potentially inappropriate medications (PIM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMG amplitude peaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of fixations to smoking cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness of OTC-Pet compared to BRC-Gly and BRC-Cer
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hazardous drinking levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean arterial blood pressure (MABP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Antiemetic efficacy for prophylaxis of chemotherapy-induced nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mild toxicity symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: sprint speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: countermovement jump height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: jump power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in leg circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg pain measured on a visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of cholangitis
Endpoint domain: Adverse events/effects
Primary endpoint: Mean hospital stay time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: neuropsychological outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: sustained amenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Antibiotic adherence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: noninferiority of zotarolimus-eluting stent compared to everolimus-eluting stent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in intake of fruits and vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: More frequent self-weighing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of stroke/transient ischemic attacks
Endpoint domain: Mortality/survival
Primary endpoint: Duration of tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quality of oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Therapeutic results on periodontitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hgb concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: DAS28 ≥ 1.2 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Time to response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recipient survival
Endpoint domain: Mortality/survival
Primary endpoint: postoperative complications (DGF and acute rejection)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean number of episodes of respiratory tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of episodes treated with antibiotics
Endpoint domain: Adverse events/effects
Primary endpoint: perception of self-worth
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PASI response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good survival
Endpoint domain: Mortality/survival
Primary endpoint: Poor survival
Endpoint domain: Mortality/survival
Primary endpoint: Days of fever
Endpoint domain: Adverse events/effects
Primary endpoint: Number of episodes of infection
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative mean pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of extraction site incision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cost savings per participant
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Brain Volume Loss (BVL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed Disability Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: probe-related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sampling-related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal procedural pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of transnasal EGD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nausea reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choking sensation reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone density at the hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bone density at the 2nd metacarpal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: spinal radiographic progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent time within target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nocturnal symptomatic hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Reduced interference with daily activities
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Reduced social burden
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Postprandial serum TAG concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Event-free survival probability
Endpoint domain: Mortality/survival